Premium
Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model
Author(s) -
Saito Momoko,
Odanaka Keita,
Otsuka Nao,
Kamachi Kazunari,
Watanabe Mineo
Publication year - 2016
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/1348-0421.12409
Subject(s) - bordetella pertussis , medicine , pertussis vaccine , virology , microbiology and biotechnology , whooping cough , potency , immunization , bordetella , vaccination , immunology , antibody , biology , bacteria , in vitro , biochemistry , genetics
Bordetella holmesii is recognized as the third causative agent of pertussis (whooping cough) in addition to Bordetella pertussis and Bordetella parapertussis . Pertussis caused by B. holmesii is not rare around the world. However, to date, there is no effective vaccine against B. holmesii . We examined the protective potency of pertussis vaccines available in Japan and vaccines prepared from B. holmesii . A murine model of respiratory infection was exploited to evaluate protective potency. No Japanese commercial pertussis vaccines were effective against B. holmesii . In contrast, a wBH vaccine and an aBH vaccine prepared from B. holmesii were both protective. Passive immunization with sera from mice immunized with aBH vaccine established protection against B. holmesii , indicating that B. holmesii ‐specific serum antibodies might play an important role in protection. Immuno‐proteomic analysis with sera from mice immunized with aBH vaccine revealed that the sera recognized a BipA‐like protein of B. holmesii . An aBH vaccine prepared from a BipA‐like protein‐deficient mutant strain did not have a protective effect against B. holmesii . Taken together, our results suggest that the BipA‐like protein plays an important role in the protective efficacy of aBH vaccine.